Lance David Miller

List of Publications by Year
in descending order

141 papers	14,670 citations	22099 59 h-index	19690 117 g-index
147 all docs	147 docs citations	147 times ranked	21135 citing authors

#	Article	IF	Citations
1	From The Cover: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13550-13555.	3.3	1,109
2	A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome. Cell, 2006, 124, 207-219.	13.5	1,060
3	Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Research, 2005, 7, R953-64.	2.2	659
4	High-fidelity mRNA amplification for gene profiling. Nature Biotechnology, 2000, 18, 457-459.	9.4	650
5	Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer. Cancer Research, 2006, 66, 10292-10301.	0.4	606
6	Whole-Genome Cartography of Estrogen Receptor Î± Binding Sites. PLoS Genetics, 2007, 3, e87.	1.5	400
7	Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis. Science Translational Medicine, 2010, 2, 43ra56.	5.8	370
8	Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF-Î¹B-Responsive Genes in Cervical Keratinocytes. Journal of Virology, 2001, 75, 4283-4296.	1.5	345
9	Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 3186-3199.	1.9	343
10	Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene, 2017, 36, 4089-4099.	2.6	320
11	Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nature Biotechnology, 2006, 24, 73-75.	9.4	279
12	Transcriptome Analysis of Zebrafish Embryogenesis Using Microarrays. PLoS Genetics, 2005, 1, e29.	1.5	272
13	Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biology, 2004, 5, R66.	13.9	257
14	Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis. Science Translational Medicine, 2010, 2, 43ra56-43ra56.	5.8	232
15	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Research, 2006, 8, R34.	2.2	218
16	Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Research, 2002, 62, 3581-6.	0.4	208
17	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. OncoImmunology, 2018, 7, e1490854.	2.1	200
18	An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer. Cancer Research, 2011, 71, 6728-6737.	0.4	181

#	Article	IF	Citations
19	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
20	Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology, 2013, 57, 1469-1483.	3.6	171
21	Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biology, 2013, 14, R34.	13.9	168
22	Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology, 2005, 42, 809-818.	3.6	167
23	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncology, The, 2017, 18, 770-778.	5.1	167
24	Identification of Cell Cycle-regulated Genes in Fission Yeast. Molecular Biology of the Cell, 2005, 16, 1026-1042.	0.9	159
25	CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells. PLoS ONE, 2009, 4, e5011.	1.1	155
26	Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biology, 2002, 3, research0035.1.	13.9	151
27	Hepcidin Regulation in Prostate and Its Disruption in Prostate Cancer. Cancer Research, 2015, 75, 2254-2263.	0.4	150
28	Optimal gene expression analysis by microarrays. Cancer Cell, 2002, 2, 353-361.	7.7	149
29	Gene Expression Preferentially Regulated by Tamoxifen in Breast Cancer Cells and Correlations with Clinical Outcome. Cancer Research, 2006, 66, 7334-7340.	0.4	149
30	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology, 2017, 6, e1253654.	2.1	146
31	Laboratory-Acquired Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2004, 350, 1740-1745.	13.9	137
32	Positive Cross-Talk between Estrogen Receptor and NF-Î²B in Breast Cancer. Cancer Research, 2009, 69, 8918-8925.	0.4	131
33	Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1488-1499.	1.9	129
34	A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers. PLoS Genetics, 2008, 4, e1000129.	1.5	127
35	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Annals of Oncology, 2012, 23, 2866-2873.	0.6	123
36	THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene, 2005, 24, 6525-6532.	2.6	120

#	Article	IF	Citations
37	DEAD-box helicase DP103 defines metastatic potential of human breast cancers. Journal of Clinical Investigation, 2014, 124, 3807-3824.	3.9	118
38	APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction. Journal of the American Society of Nephrology: JASN, 2017, 28, 1093-1105.	3.0	107
39	RCP is a human breast cancerâ€“promoting gene with Ras-activating function. Journal of Clinical Investigation, 2009, 119, 2171-83.	3.9	107
40	Tracking the Evolution of the SARS Coronavirus Using High-Throughput, High-Density Resequencing Arrays. Genome Research, 2004, 14, 398-405.	2.4	104
41	Dissecting intratumoral myeloid cell plasticity by single cell RNAâ€seq. Cancer Medicine, 2019, 8, 3072-3085.	1.3	103
42	YB-1, the E2F Pathway, and Regulation of Tumor Cell Growth. Journal of the National Cancer Institute, 2012, 104, 133-146.	3.0	102
43	IRP2 Regulates Breast Tumor Growth. Cancer Research, 2014, 74, 497-507.	0.4	100
44	Neurotensin Receptor 1 Determines the Outcome of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 4401-4410.	3.2	94
45	CT-X antigen expression in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13493-13498.	3.3	92
46	Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Research, 2007, 9, R25.	2.2	91
47	Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Annals of Surgical Oncology, 2020, 27, 1956-1967.	0.7	91
48	JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Research, 2012, 14, R85.	2.2	90
49	Yin Yang 1 contains G-quadruplex structures in its promoter and 5â€²-UTR and its expression is modulated by G4 resolvase 1. Nucleic Acids Research, 2012, 40, 1033-1049.	6.5	88
50	Yin Yang 1 Plays an Essential Role in Breast Cancer and Negatively Regulates p27. American Journal of Pathology, 2012, 180, 2120-2133.	1.9	86
51	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunology Research, 2016, 4, 600-610.	1.6	86
52	Silencing of Wnt Signaling and Activation of Multiple Metabolic Pathways in Response to Thyroid Hormone-Stimulated Cell Proliferation. Molecular and Cellular Biology, 2001, 21, 6626-6639.	1.1	85
53	A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research, 2014, 20, 5255-5264.	3.2	82
54	Transcriptome kinetics of arsenic-induced adaptive response in zebrafish liver. Physiological Genomics, 2006, 27, 351-361.	1.0	81

#	Article	IF	Citations
55	Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010â€“2014. Oncologist, 2018, 23, 481-488.	1.9	77
56	Prognostic and predictive immune gene signatures in breast cancer. Current Opinion in Oncology, 2015, 27, 433-444.	1.1	75
57	Identification of White Spot Syndrome Virus Latency-Related Genes in Specific-Pathogen-Free Shrimps by Use of a Microarray. Journal of Virology, 2003, 77, 10162-10167.	1.5	74
58	A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2018, 24, 2060-2073.	3.2	72
59	Conservation of immune gene signatures in solid tumors and prognostic implications. BMC Cancer, 2016, 16, 911.	1.1	70
60	Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma. Clinical Cancer Research, 2011, 17, 3542-3550.	3.2	65
61	RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. Frontiers in Genetics, 2011, 2, 100.	1.1	61
62	Pleural Effusion Aspirate for Use in 3D Lung Cancer Modeling and Chemotherapy Screening. ACS Biomaterials Science and Engineering, 2019, 5, 1937-1943.	2.6	58
63	HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene, 2007, 26, 3998-4008.	2.6	57
64	Disentangling the relationship between tumor genetic programs and immune responsiveness. Current Opinion in Immunology, 2016, 39, 150-158.	2.4	57
65	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
66	Functional Analysis of a Cell Cycleâ€“Associated, Tumor-Suppressive Gene, Protein Tyrosine Phosphatase Receptor Type G, in Nasopharyngeal Carcinoma. Cancer Research, 2008, 68, 8137-8145.	0.4	55
67	Trefoil Factor 3 Is Oncogenic and Mediates Anti-Estrogen Resistance in Human Mammary Carcinoma. Neoplasia, 2010, 12, 1041-IN31.	2.3	53
68	The Regulation of SOX7 and Its Tumor Suppressive Role in Breast Cancer. American Journal of Pathology, 2013, 183, 1645-1653.	1.9	52
69	Optimization and clinical validation of a pathogen detection microarray. Genome Biology, 2007, 8, R93.	13.9	51
70	EGFR and HER2 signaling in breast cancer brain metastasis. Frontiers in Bioscience - Elite, 2016, 8, 245-263.	0.9	51
71	In the pursuit of complexity: Systems medicine in cancer biology. Cancer Cell, 2006, 9, 245-247.	7.7	49
72	Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection. Cancer Research, 2009, 69, 1055-1062.	0.4	48

#	Article	IF	Citations
73	Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics, 2005, 6, 80.	1.2	47
74	Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Medicine, 2006, 4, 16.	2.3	47
75	Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. Oncotarget, 2018, 9, 13894-13910.	0.8	47
76	Gene Expression Profiling to Identify Oncogenic Determinants of Autocrine Human Growth Hormone in Human Mammary Carcinoma. Journal of Biological Chemistry, 2005, 280, 23987-24003.	1.6	46
77	Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene, 2010, 29, 3228-3240.	2.6	46
78	Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nature Nanotechnology, 2022, 17, 206-216.	15.6	46
79	Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Molecular Medicine, 2011, 3, 451-464.	3.3	45
80	Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Medicine, 2014, 6, 80.	3.6	44
81	ERRÎ± Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 1421-1431.	3.2	44
82	Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. Journal of the American College of Surgeons, 2016, 222, 493-503.	0.2	44
83	Strategies to defeat ketamine-induced neonatal brain injury. Neuroscience, 2012, 210, 384-392.	1.1	42
84	A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptorâ€“Positive Tumors. Clinical Cancer Research, 2006, 12, 3288-3296.	3.2	40
85	CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Molecular Cancer Research, 2018, 16, 1687-1700.	1.5	39
86	Activin A Promotes Regulatory T-cellâ€“Mediated Immunosuppression in Irradiated Breast Cancer. Cancer Immunology Research, 2021, 9, 89-102.	1.6	39
87	Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. Genome Biology, 2004, 5, R31.	13.9	37
88	Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Research, 2007, 9, 206.	2.2	36
89	Establishment and metabolic analysis of a model microbial community for understanding trophic and electron accepting interactions of subsurface anaerobic environments. BMC Microbiology, 2010, 10, 149.	1.3	36
90	Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. Blood, 2001, 98, 1914-1921.	0.6	35

#	Article	IF	Citations
91	Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy. Sarcoma, 2018, 2018, 1-10.	0.7	35
92	SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Research and Treatment, 2011, 129, 737-746.	1.1	34
93	Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study. Clinical Cancer Research, 2021, 27, 5141-5150.	3.2	33
94	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. Theranostics, 2017, 7, 2914-2923.	4.6	31
95	Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene, 2013, 32, 4120-4129.	2.6	30
96	The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair. Nucleic Acids Research, 2019, 47, 2703-2715.	6.5	30
97	Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorageâ€independent growth properties and impact on global gene expression in esophageal carcinoma. International Journal of Cancer, 2008, 122, 587-594.	2.3	29
98	Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Journal of Neuro-Oncology, 2014, 119, 429-435.	1.4	29
99	Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation. Journal of Molecular Cell Biology, 2016, 8, 232-243.	1.5	29
100	Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. Frontiers in Oncology, 2020, 10, 615472.	1.3	29
101	APOL1 Kidney-Risk Variants Induce Mitochondrial Fission. Kidney International Reports, 2020, 5, 891-904.	0.4	28
102	Monochromosome Transfer and Microarray Analysis Identify a Critical Tumor-Suppressive Region Mapping to Chromosome 13q14 and THSD1 in Esophageal Carcinoma. Molecular Cancer Research, 2008, 6, 592-603.	1.5	25
103	Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. Scientific Reports, 2015, 5, 12981.	1.6	25
104	Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Antiâ€“PD-1 Immune Checkpoint Blockade. Clinical Cancer Research, 2022, 28, 1192-1202.	3.2	24
105	Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients. Bioinformatics, 2006, 22, 1477-1485.	1.8	22
106	scLM: Automatic Detection of Consensus Gene Clusters Across Multiple Single-cell Datasets. Genomics, Proteomics and Bioinformatics, 2021, 19, 330-341.	3.0	22
107	Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10. Cancers, 2020, 12, 788.	1.7	16
108	Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?. Neuroradiology, 2018, 60, 1043-1051.	1.1	15

#	Article	IF	Citations
109	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296.	0.8	14
110	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296.	0.8	14
111	Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature Communications, 2022, 13, 1673.	5.8	13
112	BEARR: Batch Extraction and Analysis of cis-Regulatory Regions. Nucleic Acids Research, 2004, 32, W257-W260.	6.5	12
113	Gene profile and response to treatment. Annals of Oncology, 2005, 16, ii195-ii202.	0.6	11
114	Prognostic Molecular Classification of Appendiceal Mucinous Neoplasms Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2020, 27, 1439-1447.	0.7	11
115	Epigenetic and Posttranscriptional Modulation of SOS1 Can Promote Breast Cancer Metastasis through Obesity-Activated c-Met Signaling in African-American Women. Cancer Research, 2021, 81, 3008-3021.	0.4	11
116	A search for candidate genes for lipodystrophy, obesity and diabetes via gene expression analysis of A-ZIP/F-1 mice. Genomics, 2003, 81, 378-390.	1.3	10
117	Effects of Pubertal Exposure to Dietary Soy on Estrogen Receptor Activity in the Breast of Cynomolgus Macaques. Cancer Prevention Research, 2016, 9, 385-395.	0.7	10
118	Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. International Journal of Biological Markers, 2019, 34, 90-97.	0.7	10
119	Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. Annals of Surgical Oncology, 2020, 27, 5016-5023.	0.7	10
120	Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Journal of Neuro-Oncology, 2015, 124, 447-453.	1.4	9
121	Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types. Frontiers in Immunology, 2020, 11, 57.	2.2	8
122	Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes. Frontiers in Oncology, 2021, 11, 734959.	1.3	8
123	LOMA: A fast method to generate efficient tagged-random primers despite amplification bias of random PCR on pathogens. BMC Bioinformatics, 2008, 9, 368.	1.2	6
124	Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial). Lung Cancer, 2019, 127, 6-11.	0.9	6
125	MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells. Molecular Therapy - Oncolytics, 2020, 17, 496-507.	2.0	6
126	The Presence and Potential Role of ALDH1A2 in the Glioblastoma Microenvironment. Cells, 2021, 10, 2485.	1.8	6

#	Article	IF	Citations
127	TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4062-4062.	0.6	5
128	Comprehensive gene cluster analysis of head and neck squamous cell carcinoma TCGA RNAâ€seq data defines B cell immunityâ€related genes as a robust survival predictor. Head and Neck, 2021, , .	0.9	5
129	Identifying Driver Genes in Cancer by Triangulating Gene Expression, Gene Location, and Survival Data. Cancer Informatics, 2014, 13s6, CIN.S18302.	0.9	4
130	Toward the identification of genetic determinants of breast cancer immune responsiveness. , 2015, 3, P1.		4
131	CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Scientific Reports, 2019, 9, 14385.	1.6	4
132	Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. Clinical Breast Cancer, 2017, 17, 139-153.	1.1	3
133	Comprehensive and Computable Molecular Diagnostic Panel (C2Dx) From Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer From Fine Needle Aspirates. Frontiers in Oncology, 2021, 11, 584896.	1.3	3
134	GENOME-WIDE CDNA OLIGO PROBE DESIGN AND ITS APPLICATIONS IN SCHIZOSACCHAROMYCES POMBE. , 2004, , 347-358.		3
135	Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer. , 2014, 2, .		2
136	ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies. Annals of Surgical Oncology, 2020, 27, 5024-5025.	0.7	2
137	206â€...An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer. , 2020, 8, A222-A222.		2
138	Expression Profiling and Breast Cancer Biology. Breast Disease, 2004, 19, 29-34.	0.4	1
139	Weighted Top Score Pair Method for Gene Selection and Classification. Lecture Notes in Computer Science, 2008, , 323-333.	1.0	1
140	TMIC-36. ALDH1A2 AS A NOVEL PUTATIVE MARKER OF MACROPHAGE DIFFERENTIATION IN GBM. Neuro-Oncology, 2019, 21, vi255-vi255.	0.6	0
141	Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. Cancer, 0, , .	2.0	0